Document is current
Any future updates will be listed below
-
Authors
Shaikh, Fyza Y.
Gills, Joell J.
Mohammad, Fuad
White, James R.
Stevens, Courtney M.
Ding, Hua
Fu, Juan
Tam, Ada
Blosser, Richard L.
Domingue, Jada C.
Larman, Tatianna C.
Chaft, Jamie E.
Spicer, Jonathan D.
Reuss, Joshua E.
Naidoo, Jarushka
Forde, Patrick M.
Ganguly, Sudipto
Housseau, Franck
Pardoll, Drew M.
Sears, Cynthia L. https://orcid.org/0000-0003-4059-1661
-
Funding
Funding for this research was provided by:
Bloomberg~Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University
Bristol-Myers Squibb
National Institutes of Health (T32CA009071, P30 CA006973)
International Association for the Study of Lung Cancer
Lung Cancer Foundation of America
National Center for Advancing Translational Sciences (KL2TR001077)
Institute for Clinical and Translational Research, University of Wisconsin, Madison
LUNGevity Foundation
ECOG-ACRIN
- License Information
-
More Information
Article History
Received: 13 August 2021
Accepted: 2 February 2022
First Online: 26 February 2022
Declarations
:
: JRW reports equity ownership of Resphera Biosciences. JEC reports consultant fees for AstraZeneca, Bristol-Myers Squibb, Genentech, Merck, Flame Biosciences, Novartis, Regeneron, Guardant Health, and Jansen. JN reports research grants from Merck and AstraZeneca; consulting for AstraZeneca, Bristol-Myers Squibb, Takeda, Pfizer, Daiichi Sankyo, and Roche/Genentech; and honoraria from AstraZeneca and Bristol-Myers Squibb. PMF reports research grants from AstraZeneca, Bristol-Myers Squibb, Corvus, and Novartis. PMF reports consulting for Amgen, AstraZeneca, Bristol-Myers Squibb, Daiichi, Janssen, and Iteos. PMF reports serving as data safety monitoring board member for Flame Biosciences and Polaris. JEC reports consultant fees from AstraZeneca, Flame Biosciences, Genentech, Merck, Novartis, Jannsen. JDS has received consulting fees and honoraria from BMS, Merck, Roche, Amgen, AstraZeneca and Protalix Biotherapeutics; and he has received research grants from AstraZeneca, Merck, Roche and CLS therapeutics. JER has received advising/consulting fees from Oncocyte. DMP reports research support from AstraZeneca, Bristol Myers Squibb, and Compugen. DMP reports consulting for Aduro Biotech, Amgen, Astra Zeneca, Astellas, Bayer, Camden Partners, Compugen, DNAtrix, Dracen, Dynavax, Ervaxx, Five Prime Therapeutics, RAPT Therapeutics, Immunomic Therapeutics, Immunocore, Janssen, Merck, Potenza, Rock Springs Capital, Tizona, Trieza Therapeutics, Vaccitech, WindMil. DMP reports stock/ownership in Aduro Biotech, Dracen, Ervaxx, Five Prime Therapeutics, Tizona, Trieza Therapeutics, and WindMil. CLS reports research grants from Bristol-Myers Squibb and Janssen and personal fees from Ferring, outside the submitted work.
: All studies were approved by Johns Hopkins University Animal Care and Use Committee and Johns Hopkins Institutional Review Board.
: All authors have approved the following manuscript prior to submission.
